Amisulpride chemical structure

Find information on thousands of medical conditions and prescription drugs.

Amisulpride

Amisulpride (brand-name Solian®) is an antipsychotic drug sold by Sanofi laboratories. Amisulpride is a selective dopamine antagonist. Its dosage ranges from 200 to 1200 mg/day. Lower doses (e.g. less than 50mg) have the opposite effect and actually increase dopamine transmission. For this reason, it is sometimes used off-label in the treatment of clinical depression in low doses and for psychosis in higher doses. As for now, amisulpride is not approved by the FDA for use in the United States. more...

A

Acetylcholine chloride

Acetyldigitoxin

Alvircept sudotox

Aminocaproic acid

Aminoglutethimide

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Side effects

Parkinsonism, nausea, weight gain, and less commonly QT interval prolongation (which can lead to serious heart arrhythmias).

Read more at Wikipedia.org

• [List your site here Free!]


		Amisulpride's real-world benefit shown in schizophrenia.(Adult Psychiatry) : An article from: Clinical Psychiatry News $5.95			Amisulpride: Is there a treatment for negative symptoms in schizophrenia patients? : An article from: Schizophrenia Bulletin $20.00


	Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis Atypical antipsychotics such as amisulpride, clozapine, olanzapine, quetiapine, risperidone, and sertindole are no more effective in treating schizophrenia ... From British Medical Journal, 12/2/00 by John Geddes

	NICE decision smashes the drugs 'postcode' lottery News Update Newer, atypical anti-psychotics last month received the seal of approval from the National Institute of Clinical Excellence, in England and ... From Mental Health Nursing, 7/1/02 by Pollock, Laurence

	A nice choice Speak Up! The National Institute of Clinical Excellence is about to hand down judgement on the newer range of anti-psychotics. Tony Gillam suggests that ... From Mental Health Nursing, 3/1/02 by Gillam, Tony

	More Antipsychotics May Arrive in the United States - Brief Article PITTSBURGH -- The United States may be catching up to Europe in the number of available antipsychotic drugs, said Dr. Marc-Antoine Crocq of the Hospital ... From Family Pratice News, 3/15/00 by Heather Lindsay

	Treatment of schizophrenia - Statistical Data Included - Letter to the Editor Value of diagnosis of schizophrenia remains in dispute EDITOR--Proponents of clinical effectiveness in mental health argue that the problems of psychiatry ... From British Medical Journal, 3/18/00 by Pat Bracken

	Graduate suicide blamed on internet pharmacies LIAM BRACKELL was a brilliant, all-round student - artistic, good at science, with a loving family and a bright future. But on a sunny Sunday morning ... From Independent, The (London), 8/6/03 by Maxine Frith Social Affairs Correspondent

	After 12 Months, Largest-Ever Real-World Schizophrenia Study Shows Atypical Antipsychotics More Effective Than Typicals with Range of Differences Among Business Editors/Health/Medical Writers BERLIN--(BUSINESS WIRE)--Nov. 20, 2003 Cumulative Olanzapine Benefits vs. Other Atypicals May Lead to Better Patient Outcomes Over Time Twelve-month From Business Wire, 11/20/03

	Eli Lilly and Company: Largest-Ever International Schizophrenia Study Highlights Differences in Patient Outcomes Business Editors/Health/Medical Writers SAN FRANCISCO--(BUSINESS WIRE)--May 20, 2003 Eli Lilly and Company (NYSE:LLY) -- Naturalistic Study Provides ... From Business Wire, 5/20/03

Home

Contact

Resources

ebay